fbpx
Back to Course

Cardiology 101

0% Complete
0/0 Steps
  1. Acute Coronary Syndrome (ACS)

    Acute Coronary Syndrome (ACS) Pharmacotherapy: A Focus on STEMI
    10 Topics
    |
    3 Quizzes
  2. Hypertension
    Hypertensive Urgency and Emergency Management
    11 Topics
    |
    3 Quizzes
  3. Chronic Hypertension Pharmacotherapy
    10 Topics
    |
    3 Quizzes
  4. Heart Failure
    Acute Decompensated Heart Failure Pharmacotherapy
    10 Topics
    |
    3 Quizzes
  5. Chronic Heart Failure Pharmacotherapy
    10 Topics
    |
    3 Quizzes

Participants 396

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 1, Topic 7
In Progress

Ancillary Therapies in STEMI

Lesson Progress
0% Complete

  • Indication:
    • Relief of chest pain and discomfort
  • Mechanism:
    • Activation of μ-opioid receptor, reducing perception of pain
  • Dose:
    • 0.1 to 0.2 mg/kg IV every 5 minutes, max dose 10 mg
  • Pharmacokinetics:
    • IV Onset: 1-5 min; Duration: 2-4 hr; Metabolism: Liver
  • Adverse Effects:
    • Respiratory depression, hypotension, nausea, vomiting
  • Clinical Pearls & Practical Considerations:
    • There is limited evidence to support the routine use of morphine in ACS, and its use should be reserved for patients with severe pain and not as a first-line therapy..
    • Morphine should be used with caution in patients receiving P2Y12 inhibitors, as it can increase the risk of bleeding and delay the onset of action of these drugs.
    • Multiple studies linking its use with increased mortality

Oxygen

  • Indication:
    • Oxygen therapy (O2) is indicated for the treatment of hypoxemia in patients with acute coronary syndromes, specifically those with ST-segment elevation myocardial infarction, to improve patient outcomes.
  • Mechanism:
    • O2 therapy increases oxygen concentrations in the arterial blood and thus, the oxygen delivered to the myocardium.
    • Clinical Pearls & Practical Considerations: 
    • The AHA and ESC recommend using oxygen therapy in patients with acute coronary syndromes who are hypoxic.

Nitroglycerin

  • Indication:
    • Used to treat angina, acute coronary syndrome (including MI), and hypertension
  • Mechanism:
    • Relaxes vascular smooth muscle and reduces venous return to the heart, decreasing preload and myocardial oxygen demand
  • Dose:
    • 0.4mg SL every 5 minutes up to 3 doses; 5–20mcg/min IV infusion
  • Pharmacokinetics:
    • Rapidly absorbed after oral, SL and IV administration; metabolized in the liver
  • Adverse Effects:
    • Headache, hypotension, reflex tachycardia, nausea, vomiting
    • Clinical Pearls & Practical Considerations: 
    • Nitroglycerin should not be given to patients with hypotension, right ventricular infarction, or suspected obstructive hypertrophic cardiomyopathy.

Beta Blockers

  • Mechanism:
    • Block beta-adrenoceptors, decreasing cardiac output and peripheral vascular resistance
  • Pharmacokinetics:
    • Metabolized in the liver, half-life of 6-12 hours
  • Adverse Effects:
    • Bradycardia, hypotension, fatigue, insomnia, depression
  • Clinical Pearls & Practical Considerations:
    • Beta Blockers reduce myocardial oxygen demand and decrease the risk of recurrent myocardial infarction and ventricular arrhythmias.
    • Caution in those with Asthma, COPD, or bradycardia
    • Should be started within 24 hours of ACS unless: There are signs of HF, Active evidence of other shock states, If at increased risk of cardiogenic shock (SBP < 120 mm Hg, HR > 110 beats/min or < 60 beats/min, age > 70, and increased time since onset of symptoms)

ACE-Inhibitors

  • Mechanism:
    • Block ACE enzyme, reduce aldosterone and bradykinin, vasodilation
  • Pharmacokinetics:
    • Oral, rapid absorption, high bioavailability, excreted in urine
  • Adverse Effects:
    • Cough, hypotension, hyperkalemia, renal impairment
  • Clinical Pearls & Practical Considerations:
    • Contraindications: Hypersensitivity, renal impairment, hyperkalemia

Statins

  • Mechanism:
    • Statins are lipid-lowering medications that inhibit the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis. By reducing cholesterol levels in the body, statins can help prevent the buildup of plaque in the coronary arteries and reduce the risk of cardiovascular events.
  • Pharmacokinetics:
    • Statins are absorbed in the small intestine and undergo extensive first-pass metabolism in the liver.
    • They are metabolized by the liver and excreted in the feces.
  • Adverse Effects:
    • muscle pain, liver enzyme abnormalities, and gastrointestinal symptoms.
  • Clinical Pearls & Practical Considerations:
    • Statins are an essential component of the treatment of ACS and are recommended for all patients unless contraindicated.
    • Patients should be monitored for muscle pain and liver enzyme abnormalities while taking statins
    • It is also important to check for potential drug interactions when prescribing statin